Stockscreener 앱 받기
17.92%
시간 외 거래:
전일 마감가:
$4.27
열려 있는:
$4.1
하루 거래량:
7.61M
Relative Volume:
1.61
시가총액:
$438.94M
수익:
$409.00K
순이익/손실:
$-101.35M
주가수익비율:
-2.1372
EPS:
-1.64
순현금흐름:
$-71.49M
1주 성능:
-21.41%
1개월 성능:
-28.76%
6개월 성능:
-7.28%
1년 성능:
-38.72%
1일 변동 폭
$3.50
$4.20
1주일 범위
$3.50
$4.47
52주 변동 폭
$2.90
$7.73
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.505 | 534.74M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
Altimmune Q4 Earnings Call Highlights - MarketBeat
Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification - GuruFocus
Altimmune (ALT) Advances Liver Disease Focus with Pemvidutide - GuruFocus
Altimmune Shares Fall After Q4 Results - marketscreener.com
Altimmune Q4 2025 Earnings Call Transcript - MarketBeat
Altimmune (ALT) Shares Drop Despite Breakthrough Therapy Plans - GuruFocus
William Blair reiterates Altimmune stock rating on trial data - Investing.com
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Altimmune to start MASH late-stage trial in 2026 (ALT:NASDAQ) - Seeking Alpha
Altimmune (ALT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Altimmune Inc. misses Q4 2025 expectations, stock declines - Investing.com
Altimmune Reports 2025 Financial Results and Clinical Trial Progress with New Partnerships Formed - geneonline.com
Altimmune earnings missed by $0.02, revenue fell short of estimates - Investing.com
Altimmune (ALT) Reports Increased Revenue and Advances in Liver Disease Treatment - GuruFocus
ALTIMMUNE ($ALT) Releases Q4 2025 Earnings - Quiver Quantitative
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates - The Manila Times
Altimmune stock edges down on fourth quarter earnings miss By Investing.com - Investing.com UK
Altimmune stock edges down on fourth quarter earnings miss - Investing.com India
Altimmune (ALT) Set to Release Q4 Earnings with Anticipated EPS of -$0.24 - GuruFocus
What to Expect from Altimmune's Earnings - Benzinga
Altimmune to Participate in Upcoming Investor Conferences - Bitget
Altimmune, Inc. Announces Participation in Upcoming Investor Conferences Addressing Serious Liver Diseases - Quiver Quantitative
(ALT.O) | Stock Price & Latest News - Reuters
ALT Should I Buy - Intellectia AI
Altimmune (ALT) CSO receives stock option and RSU equity awards - Stock Titan
Altimmune (ALT) grants CFO 259,000 options and 111,000 RSUs - Stock Titan
Altimmune, Inc. (ALT) Stock Analysis: Exploring a Potential 296% Upside in Biotech Investments - DirectorsTalk Interviews
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play - Nasdaq
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - The Manila Times
Altimmune Inc (ALT.US) Stock Price, News & Analyst Forecast - eToro
Altimmune Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Aug Sectors: Does Altimmune Inc have pricing powerLayoff News & Fast Moving Market Watchlists - baoquankhu1.vn
Altimmune CEO Jerry Durso strengthens company foundation for liver disease mission - Traders Union
Altimmune, Inc. (ALT) Stock Analysis: Eyeing A Potential 293% Upside In The Biotech Space - DirectorsTalk Interviews
Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances - Finviz
MSN Money - MSN
Is Altimmune Inc. stock a good pick for beginnersWeekly Investment Report & Free Community Supported Trade Ideas - mfd.ru
Why Altimmune Inc. stock is trending among retail tradersEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
Altimmune, Inc. (ALT) Stock Analysis: Exploring A Potential 286% Upside In Biotechnology - DirectorsTalk Interviews
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - The Globe and Mail
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):